Tuoyi sold nearly 700 million in the first three quarters, and the incidence of serious adverse reactions was 11.7%
Things can be traced back to 11 On the 12th, that day, a public account article questioned the safety of Junshi Biotech’s PD-1 product Tuoyi, saying that Tuoyi had not completed trials on patients with liver and kidney damage and the adverse drug reaction rate was 97.7%. That night, the Shanghai Stock Exchange sent a letter of inquiry to Junshi Biotechnology, asking it to explain the "all adverse reaction rates", R&D team and other issues mentioned in the article.
Tuoyi’s toripalimab, independently developed by Junshi Biologics, is also the first PD-1 drug approved for marketing in China. Drug-resistant, the first indication is the treatment of patients with locally progressive or metastatic melanoma after failure of previous standard treatments. Junshi Biologics said the drug has demonstrated excellent effectiveness in a number of completed indications. The drug is currently undergoing more than 30 clinical trials of monotherapy and combination therapy worldwide, involving indications such as nasopharyngeal cancer, urothelial cancer, and lung cancer.
In the first three quarters of this year, Junshi Biotech achieved revenue of 1.011 billion yuan, a year-on-year increase of 91.84%. The Shanghai Stock Exchange also requires Junshi Biotech to disclose the specific composition of revenue and explain the report The reason for the substantial growth in operating income during the period. Junshi Biotech stated that its revenue in the first three quarters consists of three parts: product sales, patent licensing, and technical services. Revenue in the first three quarters increased by 484 million yuan. Product sales revenue increased by 195 million yuan compared with the same period last year, a year-on-year increase of 37.09%. , among which Tuoyi achieved sales revenue of 689 million yuan, a year-on-year increase of 30.91%, and patent licensing revenue increased by 209 million yuan, all of which were licensing revenue from the new crown neutralizing antibody project in cooperation with Eli Lilly and Company.
Collaboration with Eli Lilly on new coronavirus neutralizing antibody therapy has been suspended? Response: Progress is going smoothly
Junshi Biotechnology was established in December 2012. It was previously listed on the New OTC Market and later on the Hong Kong stock market. On July 15 this year, Junshi Biotech was listed on the Science and Technology Innovation Board.
Matters related to the new coronavirus neutralizing antibody project in cooperation with Eli Lilly and Company are also one of the issues that the Shanghai Stock Exchange requires Junshi Biotech to explain. In May this year, Junshi Biotech disclosed to the public that it would The exclusive license to carry out R&D activities, production and sales of its product JS016 outside Greater China has been granted to Eli Lilly and Company. Eli Lilly and Company will pay cash and sales share to the company; Eli Lilly and Company may pay 7500 in accordance with the terms and conditions agreed by both parties. US$10,000 to subscribe for the company’s newly issued H shares. An article on the public account stated that Eli Lilly and Company has announced the suspension of clinical research related to JS016. Junshi Biologics responded that in its cooperation with Eli Lilly and Company, in addition to implementing technology transfer/authorization, the two parties agreed to further negotiate for Eli Lilly and Company’s equity investment in the company. However, as of now, no legally binding share subscription contract has been signed with Eli Lilly and Company regarding the aforementioned equity investment.
Regarding the Shanghai Stock Exchange’s request to explain the scientific research background of core technical personnel, Junshi Biotech disclosed that as of now, among all the company’s employees, those with a bachelor’s degree or above The number of employees with academic qualifications accounts for 70.08% of the total number of employees. R&D personnel with bachelor's and master's degrees account for 88.23% of the total number of R&D personnel. Ph.D. and master's degrees account for 5.65% and 39.52% respectively.
Proofreading by Li Xiangling